Duration of Tamoxifen Use and the Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

PURPOSE: Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. METHODS: We studied 1504 women with a known BRCA1 or BRCA2 mutat...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Gronwald, Jacek, Robidoux, Andre, Kim-Sing, Charmaine, Tung, Nadine, Lynch, Henry T., Foulkes, William D., Manoukian, Siranoush, Ainsworth, Peter, Neuhausen, Susan, Demsky, Rochelle, Eisen, Andrea, Singer, Christian F., Saal, Howard, Senter, Leigha, Eng, Charis, Weitzel, Jeffrey, Moller, Pal, Gilchrist, Dawna M., Olopade, Olufunmilayo, Ginsburg, Ophira, Sun, Ping, Huzarski, Tomasz, Lubinski, Jan, Narod, Steven A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2014
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4131437/
https://ncbi.nlm.nih.gov/pubmed/24951267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3026-3
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन